

Ian F. Tannock

Emeritus Professor of Medicine & Medical Biophysics, Princess Margaret Cancer Centre/UHN & University of Toronto

[ian.tannock@uhn.ca](mailto:ian.tannock@uhn.ca);

Tel 416 879 8239 (mobile)

## 1. EDUCATION

### Degrees

2020	Honorary degree, Facultad de Medicina, Universidad de la República, Uruguay.
2009	D.Sc. (Med) honoris causa UK (Honorary Degree), London University, United Kingdom
1971 - 1974	MD, School of Medicine, University of Pennsylvania, Philadelphia, United States
1965 - 1968	PhD, Institute of Cancer Research, London University, England,
1962 - 1965	BA, Queens' College, Cambridge, England

### Postgraduate, Research and Specialty Training

1976 - 1978	Resident, Medical Oncology, Princess Margaret Hospital and University of Toronto, Canada
1974 - 1976	Intern & Resident, Internal Medicine, Toronto General Hospital and University of Toronto,
1968 - 1970	Postdoctoral Fellowship, Section of Experimental Radiotherapy, M.D. Anderson Hospital, Houston, Texas, United States,

### Qualifications, Certifications and Licenses

1977	Fellow, Royal College of Physicians and Surgeons of Canada, Canada
1977	Certified, Medical Oncology, American Board of Internal Medicine, United States

## 2. EMPLOYMENT

### Current Appointments

2014 July - present	Professor Emeritus, Medicine & Medical Biophysics, University of Toronto, Ontario, Canada
---------------------	---

### Previous Appointments

1978 - 2014	Staff Physician, Medical Oncology and Hematology & Senior Scientist, Research, University of Toronto, Princess Margaret Cancer Centre/University Health Network Toronto, Ontario, Canada
1995 - 2014	Faculty, Health Policy, Management & Evaluation, University of Toronto,
1989 - 2014	Professor, Medicine & Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
1997 - 2012	Endowed Chair, Daniel E. Bergsagel Professor of Medical Oncology, University of Toronto,
1990 - 1996	Chief of Medicine, Princess Margaret Hospital and Ontario Cancer Institute, Canada

## 3. HONOURS AND CAREER AWARDS (selected)

2020	<b>Honorary degree</b> , Facultad de Medicina, Universidad de la República, Uruguay.
2019	<b>ASCO</b> : Allen S. Lichter Visionary Leader Award and Lecture

2013	<b>Member, Order of Canada</b> , Government of Canada, Canada.
2012	<b>ESMO Award</b> , European Society of Medical Oncology. <i>Conferred on an ESMO member who has made an outstanding contribution to the development of oncology worldwide. First time that award was given to a non-European.</i>
2009	<b>D.Sc. (Med) honoris causa UK (Honorary Degree)</b> , London University, United Kingdom.
2008	<b>ASCO Statesman Award</b> , American Society of Clinical Oncology, United States.
2003	<b>O. Harold Warwick Prize</b> , National Cancer Institute of Canada, Toronto, Canada.
2001	<b>Professor of Survivorship Award</b> , Susan Komen Breast Cancer Foundation, United States.
1995	<b>The Spinoza Professor</b> , University of Amsterdam, Netherlands. <i>A 3-week visiting professorship involving multiple lectures and seminars The Netherlands.</i>
1992	<b>Honorary Membership</b> , European Society of Therapeutic Radiation Oncology
1992	<b>The William Rudder Fellow</b> , Queensland, Australia. <i>A 2 week Visiting Professorship in Queensland, which involved giving a total of 19 presentations.</i>
1989	<b>The Distinguished Alumnus Award</b> , M.D. Anderson Hospital, United States.

#### Teaching and Research Awards

2014	<b>Division of Medical Oncology, Education Award</b> , Dept of Medicine, Faculty of Medicine, University of Toronto <i>For longstanding teaching excellence and contributions to education.</i>
	(Divisional Teaching and Research awards received on multiple previous occasions)

#### 4. PROFESSIONAL AFFILIATIONS AND ACTIVITIES

Feb 2023	Vice-chair of 3-day site review of Tata Memorial Hospital, Mumbai (India's largest Cancer Centre). I have chaired or participated in on-site reviews of several international cancer centres.
2017-present	Member and (since 2021) Chair of the Board of Optimal Cancer Care Alliance ( <a href="https://optimalcancercare.org/">https://optimalcancercare.org/</a> ), a volunteer organization that aims to optimize dose and schedule of anticancer therapy, and to improve access to optimal treatment.
2012-2020	Member (then chair) of ASCO International Clinical Trials Working Group (now International Education Steering Group). Faculty/Organiser of multiple International Clinical trial workshops in Argentina, Chile, Croatia, Greece, Morocco, Romania, Russia, Turkey, Uruguay, Italy
2014-present	Voluntary teaching about cancer management in low and middle-income countries, including Kenya, Vietnam, India, Pakistan & Nepal.
2014-2019	Member/chair of multiple Data Safety Monitoring Committees for Academic and commercially sponsored clinical trials
2009 - 2016	Chair, Scientific Advisory Committee, European Organisation for research and Treatment of Cancer (EORTC) Brussels, Belgium. Member, EORTC Board, Brussels, Belgium.
2001-2018	Member, then vice chair of Scientific Advisory Board, Institut Curie, Paris
2001-2004	Member, ASCO Board

Numerous positions held with ASCO including Chair of Ethics Committee,

#### Academic Profile

Previous laboratory-based research: Biology of solid tumors especially their microenvironment. Drug distribution and role of autophagy in causing drug resistance.

Clinical Research: Methodological issues related to the conduct of clinical trials; Quality of life and cost-effectiveness. Clinical trials in Genitourinary and Breast Cancer.

## Research Grants

I retired from active clinical practice and research in June 2014 (but not from teaching and international advising). I held peer-reviewed grants from Canadian Institutes of Health Research, National Cancer Institute of Canada, National Institute of Health, USA, Susan Komen Foundation and other agencies throughout my career.

## International Presentations (Selected since 2019. Lectures were in person unless specified otherwise)

May 2023	National Breast Cancer Coalition. Invited presentation on “History of Breast Cancer”, Washington, DC, USA
April 2023	Course Director and Faculty: Cancer Clinical Trials Course, Rome, Italy (Presentations on “Phase 2 Trials”, “Common Causes of Bias” & “Observational Studies”)
Mar 2023	Grand Rounds on Critical Appraisal, Tata Memorial Hospital, Mumbai, India Clinical Methods Workshop (CReDO) – Faculty and lecturer (Presentations on “Protocol Writing”, “Critical Appraisal” & “Quality of Life”. Near Mumbai, India
Dec 2022	Master class on critical appraisal of the literature (to ~200 international oncologists by zoom)
Nov 2022	Presentation on “Economics of Cancer Care: Challenges in LMICs” to a meeting in India (by zoom)
Oct 2022	2 presentations on Critical evaluation of Literature and Clinical trials for European School of Oncology, Ljubljana, Slovenia
Sept 2022	2 presentations in (i) Mumbai, India, and (ii) Kathmandu, Nepal on Critical evaluation of Literature and Clinical trials supported by the Ecancer Foundation
June 2022	Debate about personalized medicine for children with cancer. Manchester, UK Best of ASCO GU. CEOC meeting, Opatija, Croatia
April 2022	Two lectures on “Clinical Trials in Africa” (by zoom to audience of African Oncologists)
Feb 2022	“Investigator-initiated research in oncology” Keynote Lecture, Tata Memorial Hospital Course on Evidence-based Medicine. Mumbai, India (virtual by zoom)
Nov 2021	“Management of prostate cancer” Hanoi Vietnam (virtual by zoom) “Advice you would give to your younger self” Sydney, Australia (virtual by zoom)
Jun/July 2021	Course director and lecturer ASCO course for West African oncologists. “How to Evaluate Medical Literature and Evidence-Based Medicine” (virtual by zoom)
May 2021	Invited lecture to Spanish cancer meeting (Madrid, Spain): “Novel therapies in prostate cancer: lessons learned” (virtual by zoom)
Feb 2021	Invited lecture: to young Indian radiation oncologists “Can we believe what we read?” (virtual by zoom) ASCO IDEA Program: “How to choose a mentor, design a study, publish and present it” (virtual by zoom)
Dec 2020	Invited lecture: “Characteristics of a good phase 3 trial and a critical review of some recent trials for GU cancer”. Shanghai cancer Centre meeting on GU oncology (virtual by zoom)
Nov/Dec 2020	Six invited lectures in workshop on “Methodology and critical appraisal”, Montevideo, Uruguay (by zoom)
June 2020	Invited lecture on “Near-Equivalence” First International Summit on Interventional Pharmacoeconomics

(by zoom)

Feb 2020	India: Clinical Methods Workshop (CReDO) – Faculty and lecturer Invited presentations at All India Institute of Medical Science, Delhi, India
June 2019	Methods in Clinical Cancer Research, Zeist NL – Lecture and faculty Central European Oncology Congress, Opatija, Croatia – 2 presentations ASCO Annual Meeting: Allen S Lichter Award Lecture and Education lecture
Mar 2019	India: Clinical Methods Workshop (CReDO) – Faculty and lecturer
Jan 2019	Eilat, Israel: Invited guest speaker at Israeli Cancer Meeting (3 presentations) + invited talks in Jerusalem, Tel Aviv and Amman Jordan

### Volunteer Teaching in Developing Countries

Sept 2020	3 days intensive teaching of residents in each of Dharan and Kathmandu, Nepal
April 2019	2 weeks volunteer teaching in Kathmandu, Nepal sponsored by ASCO/HVO
Nov 2018	Shaukat Khanum Cancer Centre, Lahore Pakistan; 2 days teaching trainees in medical and radiation oncology
Feb 2017	Chennai, India: Five presentations at WIA cancer institute. Faculty at week-long CREDO clinical trials workshop, near Mumbai, India
Dec 2016	Hue, Da Nang and Hanoi, Vietnam: Two weeks teaching and advising on breast and other cancers as part of ASCO/Health Volunteers Overseas team
March 2016	Lahore, Pakistan: One week full-time course on medical oncology given to ~30 young oncologists from various cities in Pakistan
March 2016	Mumbai, India: Teaching Lectures at Tata Memorial Hospital
Nov 2015	Eldoret, Kenya: Two-week stay with multiple presentations to clinical officers training in oncology, discussion of cancer patients with staff and trainees in clinics and on hospital rounds
2014 Nov/Dec	Hanoi and Hue, Vietnam: Multiple presentations (on clinical trials, prostate, bladder, kidney and breast cancer) at National Cancer Institute.

### Publications

**TEXTBOOK:** The Basic Science of Oncology. Now in its 6th Edition. Harrington L, Tannock I, Hill R, Cescon D, editor(s).: McGraw-Hill; 2021. Used widely to teach trainees in all branches of oncology world-wide.

**PEER-REVIEWED PUBLICATIONS** (Selected from total of >480 lifetime, ~50 since 2019; h-index = 125)

**Tannock IF**, Bouche G, Goldstein DA, et al. Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy. Ann Oncol. 2023 Epub ahead of print.

Meirson T, Goldstein DA, Gyawali B, **Tannock IF**. Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer. Lancet Oncol. 2023;24:589-93.

**Tannock IF**, Goldstein DA, Ofer J, Gyawali B, Meirson T. Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer? J Clin Oncol. 2023;41:2713-7.

**Tannock IF**, Steel GG. Cell proliferation, drug distribution and therapeutic effects in relation to the vascular system of solid tumours. Br J Cancer. 2023; 128:313-8

Salawu A, **Tannock IF**. Rules for the conduct of clinical trials need revision, but 'good clinical practice' requires much more. *Ann Oncol*. 2022;34:4-6

Hirsch I, Goldstein DA, **Tannock IF**, Butler MO, Gilbert DC. Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access. *Nat Med*. 202;28:2236-7.

Kartolo A, **Tannock IF**, Vera Badillo FE. Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed? *J Clin Oncol*. 2022; 40, 3573-5.

**Tannock IF**, Pond GR, Booth CM. Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead. *JAMA Oncol*. 2022;8:679-680.

Patel A, Goldstein DA, **Tannock IF**. Improving access to immunotherapy in low- and middle-income countries. *Ann Oncol*. 2022;33:360-361.

Desnoyers A, Amir E, **Tannock IF**. Adjuvant Zoledronate Therapy for Women with Breast Cancer-Effective Treatment or Fool's Gold? *JAMA Oncol*. 2021;7:1121-1123.

Chan KK, **Tannock IF**. Should Basket Trials Be Pathways to Drug Registration for Biomarker-Defined Subgroups of Advanced Cancers? *J Clin Oncol*. 2021;39:2426-2429

Fundytus A, Booth CM, **Tannock IF**. How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy. *Ann Oncol*. 2021;32:833-836.

Elimova E, Moignard S, Li X, Yu M, Xu W, Seruga B, **Tannock IF**. Updating Reports of Phase 3 Clinical Trials for Cancer. *JAMA Oncol*. 2021;7:593-596.

**Tannock IF**, Ratain MJ, Goldstein DA, Lichter AS, Rosner GL, Saltz LB. Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. *J Clin Oncol*. 2021;39:950-955.

**Tannock IF**. Have investigators forgotten how to write? *Ann Oncol*. 2021;32:437-438.

Del Paggio JC, **Tannock IF**. Cautionary tails. *Ann Oncol*. 2021;32:20-22.

Joshua AM, **Tannock IF**. Oncology in 2050 - A Retrospective? *Oncologist*. 2020;25:e1127-e1130.

Templeton AJ, Amir E, **Tannock IF**. Informative censoring - a neglected cause of bias in oncology trials. *Nat Rev Clin Oncol*. 2020;17:327-328.

Templeton AJ, Booth CM, **Tannock IF**. Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap. *J Clin Oncol*. 2020;38:1651-1654.

Patel A, **Tannock IF**, et al. Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets. *JCO Glob Oncol*. 2020;6:382-386.

**Tannock IF**, Templeton AJ Flawed trials for cancer. *Ann Oncol*. 2020;31:331-333.

Joshua AM, **Tannock IF**. Companion Diagnostics to Identify Biomarkers of Response to Anticancer Drugs Targeting the Proteome. *Cancer Cell*. 2019;36:464-465.

Del Paggio JC, **Tannock IF**. The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis. *Lancet Oncol*. 2019;20:1065-9.

**Tannock IF**. Improving Treatment for Advanced Prostate Cancer. *N Engl J Med*. 2019;381:176-7.

Vera-Badillo FE, **Tannock IF**, Booth CM. Immunotherapy for Urothelial Cancer: Where Are the Randomized Trials? *J Clin Oncol* 2019;37:2587-2591.

**Tannock IF**. Disclosure-in the blink of an eye. *Ann Oncol* 2019;30:169-170.

Kimmelman J, **Tannock I**. The paradox of precision medicine. *Nat Rev Clin Oncol* 2018;15:341-2.

**Tannock IF**, Joshua AM. Purchasing Silence. *Ann Oncol* 2018;29:1339-40.

**Tannock IF**. Abiraterone in Metastatic Prostate Cancer. *N Engl J Med*. 2017;377:1695

## OLDER HIGH IMPACT PUBLICATIONS

- Tannock IF**, Amir E, Booth CM, Niraula S, Ocana A, Seruga B, Templeton AJ, Vera-Badillo F. Relevance of randomised controlled trials in oncology. *Lancet Oncol*. 2016;17:e560-7.
- Seruga B, Templeton AJ, Badillo FE, Ocana A, Amir E, **Tannock IF**. Under-reporting of harm in clinical trials. *Lancet Oncol*. 2016;17:e209-19.
- Templeton AJ, McNamara MG, Šeruga B .. **Tannock IF**, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *J Natl Cancer Inst*. 2014;106(6):
- Zimmermann C, Swami N, Krzyzanowska M, .. **Tannock I**, Donner A, Lo C. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. *Lancet*. 2014;383:1721-30.
- Ocana A, Pandiella A, Siu LL, **Tannock IF**. Preclinical development of molecular-targeted agents for cancer. *Nat Rev Clin Oncol*. 2010;8:200-9
- Scher HI, Halabi S, **Tannock I**, et al. Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. *J Clin Oncol*. 2008;26:1148-59.
- Trédan O, Galmarini CM, Patel K, **Tannock IF**. Drug resistance and the tumor microenvironment. *JNCI* 2007;99; 1441-54
- Minchinton AI, **Tannock IF**. Drug penetration in solid tumours. *Nat Rev Cancer* 2006;6:583-92
- Kim JJ, **Tannock IF**. Repopulation of cancer cells during therapy: an important cause of treatment failure. *Nat Rev Cancer* 2005;5; 516-25
- Tannock IF**, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer *New Engl J Med* 2004;351: 1502-12
- Tannock IF**, Osoba D, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian trial with palliative end points. *J Clin Oncol* 1996;14;1756-64
- Tannock IF**, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. *Cancer Res* 1989;49;4373-84
- Selby P, Buick RN, **Tannock I**. A critical appraisal of the human tumor stem-cell assay. *N Engl J Med* 1983;308;129-34